Migliori GB, et al. - The World Health Organization created a global initiative, known as aDSM (active TB drug safety monitoring and management), with the aim of showing the feasibility of implementing national aDSM registers and to summarize the type and frequency of adverse events (AEs) associated with exposure to the new anti-tuberculosis (TB) drugs. After a pilot study carried out in 2016, TB reference centers/countries were sought for official involvement in the project and consecutive recruitment of cases treated with bedaquiline- and/or delamanid-containing regimens was done. Out of 781 cases countries committed to report in 2019, a total of 309 cases were fully reported as of February 2019 (65% males; 268 treated with bedaquiline, 20 with delamanid, and 21 with both drugs) from 41 centers in 27 countries.